Cord blood (CB) transplantation is primarily performed in children. Two major obstacles which limit its potential as a conventional source of hematopoietic stem cells (HSC) for allogeneic transplantation in adults are the inadequately low number of hematopoietic progenitor cells obtained from a single CB collection and the prolonged thrombocytopenia often encountered following CB transplantation (CBT). Efforts are currently underway to expand the number of CB progenitor and HSC ex vivo, to enable transplantation in adults. We have previously demonstrated that transplantation of ex-vivo expanded megakaryocyte (Mk) precursors in marrow allografts enhanced platelet recovery post BMT. In this study, we investigated different techniques for enrichment and expansion of Mk progenitor cells and HSC from CB. CBs from 26 normal deliveries were divided into 4 aliquots and depleted of RBC using 3% gelatin, Hespan, Ficoll-Paque or a two-step 3% gelatin followed by FicollPaque separation. The two-step procedure was found to be superior to the other methods in enrichment of the Mk progenitor cells (CFU-Mk) (34.3-fold) while retaining the number of myeloid and erythroid progenitors, as well as CD34 + and CD41 + cells. In short-term (14 days) liquid cultures of non-adherent nucleated cells isolated by gelatin and Ficoll-Paque, a 40-fold expansion of cloneable Mk progenitor cells was obtained in the presence of thrombopoietin (r-hu-TPO) and stem cell factor (r-hu-SCF) as well as a 6 fold increase in the number of CFU-GM with no loss of BFU-E. In similar cultures of isolated CD34
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+ cells, a 100-fold increase in the cloneable Mk progenitors was obtained at day 14 as compared to 21.3-fold with r-hu-TPO alone and no expansion with SCF alone. Furthermore with the combination of TPO and SCF the myeloid progenitors CFU-GM were expanded 20-fold and erythroid progenitors BFU-E 5-fold by day 7. Thus, this technique followed by short term cultures (up to 14 days) provide an efficient and suitable method for the ex vivo expansion of Mk progenitor cells prior to transplantation. Transplantation in patients will determine the efficacy of expanded progenitors to facilitate earlier platelet production. We studied the effect of stem cell factor (SCF), interleukin 3 (IL-3) and interleukin 11 (IL-11) on the proliferation of human CD34 . This means that the absolute number of CD34 cells increased slightly, the number of CD33 increased 100 times and the cells with a high density CD71 high (23%) appeared. These cells represent the cells committed at erythroid differentiation. The increase in the number of CFU-GM with various combinations of cytokines SCF+IL-3+IL-11 will be discussed. The number of CFU-GM in culture after a seven-day ex vivo expansion in the presence of SCF+IL-3+IL-11 increased 45 times.
S25 EX VIVO EXPANSION SELECTED AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELLS (PBPC) IN

Keywords: CD34
+ cells, AC133 + cells, progenitor cells, ex vivo expansion, breast cancer, intensive chemotherapy S26
